HCK as a therapeutic target in MYD88 mutated diseases
US10525060B2 · kind B2 · utility
3Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2017 |
| Grant date | Jan 7, 2020 |
| Priority date | — |
| Expiry date | Apr 28, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treatment of conditions or diseases associated with myeloid differentiation primary response (MYD88) protein using a selective HCK inhibitor are provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.